These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 15848557)

  • 1. Standard dose enteric-coated mycophenolate sodium (myfortic) delivers rapid therapeutic mycophenolic acid exposure in kidney transplant recipients.
    Sumethkul V; Na-Bangchang K; Kantachuvesiri S; Jirasiritham S
    Transplant Proc; 2005 Mar; 37(2):861-3. PubMed ID: 15848557
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lower dosing of enteric-coated mycophenolate sodium (Myfortic) can achieve target mycophenolic acid exposure rapidly in most Chinese renal transplant patients: a pilot study.
    Yin H; Qiu K; Hu XP; Li XB; Wang W; Liu LH; Zhang XD
    Int J Clin Pract Suppl; 2014 Apr; (181):31-7. PubMed ID: 24673717
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enteric-coated mycophenolate sodium delivers bioequivalent MPA exposure compared with mycophenolate mofetil.
    Arns W; Breuer S; Choudhury S; Taccard G; Lee J; Binder V; Roettele J; Schmouder R
    Clin Transplant; 2005 Apr; 19(2):199-206. PubMed ID: 15740555
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development and validation of limited sampling strategies for the estimation of mycophenolic acid area under the curve in adult kidney and liver transplant recipients receiving concomitant enteric-coated mycophenolate sodium and tacrolimus.
    Pawinski T; Luszczynska P; Durlik M; Majchrzak J; Baczkowska T; Chrzanowska M; Sobiak J; Glyda M; Kuriata-Kordek M; Kamińska D; Krajewska M; Klinger M
    Ther Drug Monit; 2013 Dec; 35(6):760-9. PubMed ID: 24192641
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics of enteric-coated mycophenolate sodium in stable pediatric renal transplant recipients.
    Ettenger R; Bartosh S; Choi L; Zhu W; Niederberger W; Campestrini J; Bastien MC; Schmouder R
    Pediatr Transplant; 2005 Dec; 9(6):780-7. PubMed ID: 16269051
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Which is more suitable for kidney transplantation at the early post-transplantation phase in China - low dosing or standard dosing of enteric-coated mycophenolate sodium?
    Ding C; Xue W; Tian P; Ding X; Pan X; Xiang H; Tian X; Li Y; Zheng J
    Int J Clin Pract Suppl; 2014 Apr; (181):10-6. PubMed ID: 24673714
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cyclosporine A and tacrolimus combined with enteric-coated mycophenolate sodium influence the plasma mycophenolic acid concentration - a randomised controlled trial in Chinese live related donor kidney transplant recipients.
    Huang HF; Yao X; Chen Y; Xie WQ; Shen-Tu JZ; Chen JH
    Int J Clin Pract Suppl; 2014 Apr; (181):4-9. PubMed ID: 24673713
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mycophenolic acid metabolite profile in renal transplant patients receiving enteric-coated mycophenolate sodium or mycophenolate mofetil.
    Tedesco-Silva H; Bastien MC; Choi L; Felipe C; Campestrini J; Picard F; Schmouder R
    Transplant Proc; 2005 Mar; 37(2):852-5. PubMed ID: 15848554
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evalutation of mycophenolic acid systemic exposure by limited sampling strategy in kidney transplant recipients receiving enteric-coated mycophenolate sodium (EC-MPS) and cyclosporine.
    Capone D; Tarantino G; Kadilli I; Polichetti G; Basile V; Federico S; Sabbatini M
    Nephrol Dial Transplant; 2011 Sep; 26(9):3019-25. PubMed ID: 21317409
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapeutic drug monitoring of mycophenolate mofetil and enteric-coated mycophenolate sodium in patients with systemic lupus erythematosus.
    Djabarouti S; Duffau P; Lazaro E; Chapouly C; Greib C; Viallard JF; Pellegrin JL; Saux MC; Breilh D
    Expert Opin Pharmacother; 2010 Apr; 11(5):689-99. PubMed ID: 20210680
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics and variability of mycophenolic acid from enteric-coated mycophenolate sodium compared with mycophenolate mofetil in de novo heart transplant recipients.
    Hummel M; Yonan N; Ross H; Miller LW; Sechaud R; Balez S; Koelle EU; Gerosa G;
    Clin Transplant; 2007; 21(1):18-23. PubMed ID: 17302587
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Better mycophenolic acid 12-hour trough level after enteric-coated mycophenolate sodium in patients with gastrointestinal intolerance to mycophenolate mofetil.
    Sánchez Fructuoso A; Calvo N; Moreno MA; Giorgi M; Conesa J; Barrientos A
    Transplant Proc; 2007 Sep; 39(7):2194-6. PubMed ID: 17889135
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in maintenance renal transplant recipients receiving tacrolimus: clinical, pharmacokinetic, and pharmacodynamic outcomes.
    Budde K; Glander P; Krämer BK; Fischer W; Hoffmann U; Bauer S; Grohmann J; Neumayer HH; Arns W
    Transplantation; 2007 Feb; 83(4):417-24. PubMed ID: 17318074
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of mycophenolic acid pharmacokinetic parameters in kidney transplant patients within the first 3 months post-transplant.
    Pawinski T; Durlik M; Szlaska I; Urbanowicz A; Majchrnak J; Gralak B
    J Clin Pharm Ther; 2006 Feb; 31(1):27-34. PubMed ID: 16476117
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Absorption characteristics of EC-MPS--an enteric-coated formulation of mycophenolic sodium.
    Arns W; Gies M; Choi L; Zhu W; Cooper P; Yeh CM; Prasad P; Graf P; Schmouder R
    Int J Clin Pharmacol Ther; 2006 Aug; 44(8):375-85. PubMed ID: 16961168
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics and pharmacodynamics in renal transplant recipients under treatment with cyclosporine and Myfortic.
    Brunet M; Crespo M; Millán O; Serón D; Torregrosa V; Jiménez O; Moreso F; Martorell J; Grinyo JM; Oppenheimer F
    Transplant Proc; 2007 Sep; 39(7):2160-2. PubMed ID: 17889124
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics of enteric-coated mycophenolate sodium: comparative study in patients with autoimmune disease and renal allograft.
    Neumann I; Fuhrmann H; Kanzler M; Fang IF; Jaeger A; Graf H; Bayer P; Kovarik J
    Expert Opin Pharmacother; 2008 Apr; 9(6):879-86. PubMed ID: 18377332
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Stable renal transplant recipients can be safely converted from MMF to enteric-coated mycophenolate sodium tablets: Interim results of a multicenter Latin American study.
    Abbud-Filho M; Girón F; Hernández E; Juarez F; Liendo C; Novoa P; Toledo M;
    Transplant Proc; 2004; 36(6):1647-9. PubMed ID: 15350440
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bioequivalence of enteric-coated mycophenolate sodium and mycophenolate mofetil: a meta-analysis of three studies in stable renal transplant recipients.
    Johnston A; He X; Holt DW
    Transplantation; 2006 Dec; 82(11):1413-8. PubMed ID: 17164710
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetic and pharmacodynamic analysis of enteric-coated mycophenolate sodium: limited sampling strategies and clinical outcome in renal transplant patients.
    Sommerer C; Müller-Krebs S; Schaier M; Glander P; Budde K; Schwenger V; Mikus G; Zeier M
    Br J Clin Pharmacol; 2010 Apr; 69(4):346-57. PubMed ID: 20406219
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.